News | Cath Lab | October 27, 2016

Better Prognosis for Some PCI Patients When Operators Perform More Procedures

Patients needing more complex PCIs have better outcomes, according to Chinese study

PCI, operator volume, China study, JACC, outcomes

October 27, 2016 — Volume matters when it comes to who does certain procedures to removing heart-attack causing blockages from arteries, according to a new study published recently in JACC: Cardiovascular Interventions.

Researchers in China found patients undergoing left main coronary artery percutaneous coronary intervention (PCI) had better outcomes when the procedure was performed by experienced, high-volume operators — even though the patients treated by the experienced operators tended to have more complex and extensive heart disease. Left-main PCI can be used to treat patients with advanced coronary artery disease. In this procedure, a drug-eluting stent is placed in the left main coronary artery to open the blockage. The technique is minimally invasive and has been associated with fewer complications, short hospital stays and quicker recovery time than coronary artery bypass graft (CABG) surgery.

The researchers examined the records of 1,948 patients who underwent left-main PCI between January 2004 and December 2011, with 25 operators performing the procedure. Of those patients, 1,422 (73 percent) were treated by seven experienced, high-volume operators and 526 (27 percent) patients were treated by 18 less experienced, low-volume operators. High-volume operators performed a mean of 25 left-main PCIs per year, while low-volume operators performed a mean of four left-main PCIs per year. 

Patients treated by high-volume operators had better short- and long-term outcomes. Death within 30 days was 0.6 percent with high-volume operators and 2.1 percent with low-volume operators. There was no significant difference in rates of heart attack, and stroke over the same time period were lower in patients treated by high-volume operators. Patients of high-volume operators also had lower risks of cardiac death and all-cause mortality, as well as a trend toward a decreased risk of stent thrombosis.

After three years, patients treated by experienced, high-volume operators experienced a significantly lower risk of cardiac death.

These trends were observed even though patients who underwent left-main PCI with a high-volume operator had more extensive coronary artery disease and underwent more technically complex procedures. High-volume operators were also more likely to use first-generation, rather than superior second-generation, drug-eluting stents.

This is the first study to conclusively demonstrate that operator experience impacts the prognosis of patients who undergo high-risk PCI.

“Our findings suggest that high-risk and complex procedures, such as left-main PCI, should be reserved to a limited number of experienced operators in order to achieve the best outcomes,” said Yuejin Yang, M.D., from the department of cardiology at Fu Wai Hospital in Beijing and an author of the study. “Alternatively, less experienced operators could perform left-main PCI under the close supervision and mentorship of an experienced operator until they acquire sufficient skill and technique to become independent.”

In an editorial comment accompanying the study, Ralph G. Brindis, M.D., MPH, MACC, and Gregory J. Dehmer, M.D., MACC, examined data from the American College of Cardiology’s (ACC) National Cardiovascular Data Registry’s (NCDR) CathPCI Registry to determine the  amount of left-main PCI’s performed by high- and low-volume operators in the United States. They found that for left-main PCIs performed between April 2015 and March 2016, only 1 percent of operators would be considered high-volume based on the study’s criteria of having performed at least 15 left-main PCI’s per year for at least three consecutive years. Additionally, these operators performed only 8.4 percent of these annual procedures in the United States.

“These numbers are a stark contrast compared with the results of the study by Yang and colleagues and perhaps should be a wake-up call to the interventional community,” Brindis and Dehmer said. “The concept of a ‘Center of Excellence’ has been widely promoted and, frankly, overused to the point it now has little meaning. The study findings show that a ‘Center of Excellence’ for left-main PCI should be one with experienced, high-volume operators that can demonstrate good outcomes.”

Related NCDR CathPCI Registry articles:

• Radial Access, Same-Day Cardiac Procedure Could Save $300 Million Annually

• New Report Highlights National Trends in Heart Disease Treatments

• Study Finds Significant Variability in Doctors' Angioplasty Death Rates

 

For more information: www.jacc.org

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init